Development of Renal Disorder in a Patient Receiving Infliximab (Remicade(R)) for Psoriasis / 대한피부과학회지
Korean Journal of Dermatology
; : 494-497, 2014.
Article
en Ko
| WPRIM
| ID: wpr-122328
Biblioteca responsable:
WPRO
ABSTRACT
Infliximab (Remicade(R)) has been used for treating many chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. Complications such as infusion reaction and infection in infliximab therapy have been reported, but renal complications are rare. We present data on a patient with psoriasis for 15 years who developed new onset renal disorders (IgA nephropathy, acute tubulointerstitial nephritis, acute tubular necrosis) after treatment with infliximab (duration of therapy: 12 months, 8 times). Because the patient with psoriasis receiving infliximab may develop new onset renal disorders, we recommend the evaluation of renal function.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Artritis Reumatoide
/
Psoriasis
/
Espondilitis Anquilosante
/
Enfermedad de Crohn
/
Infliximab
/
Nefritis Intersticial
Límite:
Humans
Idioma:
Ko
Revista:
Korean Journal of Dermatology
Año:
2014
Tipo del documento:
Article